Andreas Ziegler

List of Publications by Year
in descending order

18	710	759233 12	677142 22
papers	citations	h-index	g-index

23	23	23	943
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurology, The, 2020, 19, 317-325.	10.2	196
2	Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2â€‰years of age â€“ a multicenter retrospective study. Orphanet Journal of Rare Diseases, 2019, 14, 96.	2.7	90
3	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. European Journal of Paediatric Neurology, 2020, 28, 38-43.	1.6	74
4	Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. The Lancet Child and Adolescent Health, 2022, 6, 17-27.	5.6	57
5	Cerebrospinal fluid proteomic profiling in nusinersenâ€treated patients with spinal muscular atrophy. Journal of Neurochemistry, 2020, 153, 650-661.	3.9	44
6	Pathogenic WDFY3 variants cause neurodevelopmental disorders and opposing effects on brain size. Brain, 2019, 142, 2617-2630.	7.6	31
7	Novel challenges in spinal muscular atrophy â€“ How to screen and whom to treat?. Annals of Clinical and Translational Neurology, 2019, 6, 197-205.	3.7	30
8	Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. Brain, 2020, 143, 2929-2944.	7.6	29
9	CASPR2 autoimmunity in children expanding to mild encephalopathy with hypertension. Neurology, 2020, 94, e2290-e2301.	1.1	26
10	Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy. Neurology, 2019, 93, e653-e664.	1.1	24
11	Biallelic and monoallelic variants in PLXNA1 are implicated in a novel neurodevelopmental disorder with variable cerebral and eye anomalies. Genetics in Medicine, 2021, 23, 1715-1725.	2.4	22
12	Cathepsin D as biomarker in cerebrospinal fluid of nusinersenâ€treated patients with spinal muscular atrophy. European Journal of Neurology, 2022, 29, 2084-2096.	3.3	13
13	Bi-allelic variants in SPATA5L1 lead to intellectual disability, spastic-dystonic cerebral palsy, epilepsy, and hearing loss. American Journal of Human Genetics, 2021, 108, 2006-2016.	6.2	11
14	1H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 441.	2.7	8
15	Serological and biochemical characterization of HLA-A molecules bearing a public epitope. Immunogenetics, 1988, 27, 61-65.	2.4	5
16	Axenfeld-Rieger Anomaly and Neuropsychiatric Problemsâ€"More than Meets the Eye. Neuropediatrics, 2020, 51, 192-197.	0.6	5
17	Response to letter: A decision for life â€“ Treatment decisions in newly diagnosed families with spinal muscular atrophy. European Journal of Paediatric Neurology, 2021, 30, 103-104.	1.6	1
18	Mitochondrial Transporter Defects: Successful Treatment with Ketogenic Diet Therapy. Neuropediatrics, 2021, 52, .	0.6	0